Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
147.98
-0.10 (-0.07%)
At close: Sep 24, 2026, 4:00 PM EDT
148.09
+0.11 (0.07%)
After-hours: Sep 24, 2026, 7:45 PM EDT
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$887,587
Profits / Employee
$42,307
Market Cap
365.09B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
MRK News
- 9 hours ago - FDA approves Welireg and Lenvima combo for ccRCC - TheFly
- 18 hours ago - Merck's eye disease drug meets main goal in trial - Reuters
- 18 hours ago - Merck’s remigromig meets primary endpoint in Phase 2b/3 DME trial - TheFly
- 18 hours ago - Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema - Business Wire
- 2 days ago - Merck says FDA approves update for U.S. product label for Winrevair - TheFly
- 2 days ago - U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) - Business Wire
- 3 days ago - Pharmaceutical Companies Push Trump Administration to Protect China Deals - WSJ
- 3 days ago - Merck says Japan’s MHLW approves Keytruda Qlex - TheFly